Couldn’t sleep well tonight so I spent time re-reading the most recent 8-k…given the perspective of hindsight and some context from other posters, plus a very noticeable quiet period I looked into PPD to see what they are all about…then went to their vaccine section and there were some videos in their registration protected area where you just have to put in your details to view…I’ve provided the link below.
https://www.ppd.com/therapeutic-expertise/vac...ates#gf_55
PPD is the real deal plus when you overlay PPD’s capabilities with the widely accepted method that GNBT highlighted some time ago where they are able to potentially gain phase 3 data from hitting multiple qualified AI identified worldwide sites to ensure trial engagement and see how their vaccine candidates do within different populations & variants. It may be that GNBT, by being deliberate and taking it slowly will gain the benefit of being able to use the newest most heavily validated models and leapfrog all other vaccines to become the worldwide candidate to provide premier vaccination and T-Cell memory.
If you take 25 mins to watch the videos and read the blurb about how PPD was impactful within the Moderna trials the picture seems to become more clear with the benefit of hindsight…makes sense to me why Joe is tipping his glass these days looking satisfied with his work seemingly paying off.
Although my analysis is wrought with speculation, I think that I do a pretty good job of reading context as that is what I do on a daily basis in my professional world. (I could also just be wrong too…but I don’t think I am)
Perhaps the 8-k or PR should have been titled:
“NGIO signs agreement with the same company as Moderna who successfully used it to conduct its large phase trials and subsequently gain vaccine commercialization.”
With the benefit of hindsight, we also now know that data suggests (RJs post from yesterday) that Moderna provides the most memory of any current approved vaccine (if only by a month).
When combining the expertise with the experience of PPD and the predictive models of both epivax on the front end for vaccine candidate development with enhanced AI that was quickly adopted as a new gold standard by the FDA, and PPD on the back end for trial identification, selection and execution, GNBT/NGIO has taken its time to develop the most promising vaccine candidates to date that when now combined with the potential for Ii-key memory durability NGIO has used best-in-class resources to develop the most promising possible vaccine known to humanity.
I believe it’s possible…
https://www.ppd.com/therapeutic-expertise/vac...ates#gf_55
PPD is the real deal plus when you overlay PPD’s capabilities with the widely accepted method that GNBT highlighted some time ago where they are able to potentially gain phase 3 data from hitting multiple qualified AI identified worldwide sites to ensure trial engagement and see how their vaccine candidates do within different populations & variants. It may be that GNBT, by being deliberate and taking it slowly will gain the benefit of being able to use the newest most heavily validated models and leapfrog all other vaccines to become the worldwide candidate to provide premier vaccination and T-Cell memory.
If you take 25 mins to watch the videos and read the blurb about how PPD was impactful within the Moderna trials the picture seems to become more clear with the benefit of hindsight…makes sense to me why Joe is tipping his glass these days looking satisfied with his work seemingly paying off.
Although my analysis is wrought with speculation, I think that I do a pretty good job of reading context as that is what I do on a daily basis in my professional world. (I could also just be wrong too…but I don’t think I am)
Perhaps the 8-k or PR should have been titled:
“NGIO signs agreement with the same company as Moderna who successfully used it to conduct its large phase trials and subsequently gain vaccine commercialization.”
With the benefit of hindsight, we also now know that data suggests (RJs post from yesterday) that Moderna provides the most memory of any current approved vaccine (if only by a month).
When combining the expertise with the experience of PPD and the predictive models of both epivax on the front end for vaccine candidate development with enhanced AI that was quickly adopted as a new gold standard by the FDA, and PPD on the back end for trial identification, selection and execution, GNBT/NGIO has taken its time to develop the most promising vaccine candidates to date that when now combined with the potential for Ii-key memory durability NGIO has used best-in-class resources to develop the most promising possible vaccine known to humanity.
I believe it’s possible…
9
